Rapport Reveals Promising Phase 2a Data for RAP-219 Epilepsy Pill, Plans Phase 3 Trials on September 08, 2025 anti-seizure medication clinical development drug-resistant epilepsy Epilepsy focal onset seizures RAP-219 Rapport Therapeutics Seizures +
Praxis touts 'best-in-disease' epilepsy data, but shares dip on August 05, 2025 anti-seizure medication Clinical Research Clinical Trials Epilepsy focal onset seizures Market Praxis Precision Medicines Radiant heater Seizures vormatrigine +